Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.
Ontology highlight
ABSTRACT: Combined lenalidomide and dexamethasone is a standard-of-care therapy for the treatment of older adults with multiple myeloma. Lenalidomide monotherapy has not been evaluated in newly diagnosed myeloma patients. We conducted a phase II study, evaluating a response-adapted therapy for older adults newly diagnosed with multiple myeloma without high-risk features who were ineligible for high-dose therapy and stem cell transplant. Patients were started on single-agent lenalidomide, and low-dose dexamethasone was added in the event of progressive disease, in a response-adapted approach. The primary endpoint was progression-free survival (PFS), and the International Myeloma Working Group's uniform response criteria were used to assess response and progression. Twenty-seven patients were enrolled
SUBMITTER: Baz R
PROVIDER: S-EPMC7771320 | biostudies-literature | 2019 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA